Bristol Myers schizophrenia therapy safe in late-stage trial Markets April 6, 2024 [ad_1] hapabapa/iStock Editorial through Getty Pictures Bristol Myers Squibb (NYSE:BMY) introduced Saturday that its experimental schizophrenia remedy KarXT, acquired as…
Infographic: How Bristol Myers Squibb (BMY) performed in Q4 2023 financial results Markets February 5, 2024 [ad_1] Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2023 earnings outcomes right this moment. Complete revenues inched up 1%…
